Frazier Life Sciences Management, L.P.
Frazier Life Sciences Management, L.P. reported 41 holdings worth US$4.59B as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Aug 14, 2026
Frazier Life Sciences Management, L.P. reported 41 holdings worth US$4.59B as of Jun 30, 2026. Largest: Mirum Pharmaceuticals, Inc., Erasca, Inc. and Mbx Biosciences, Inc. Filed Aug 14, 2026 (Form 13F).
- Holdings
- 41
- Value as reported
- US$4.59B
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|
| Mirum Pharmaceuticals, Inc. | 7.68M | US$899M | 19.6% |
| Erasca, Inc. | 25M | US$458M | 10.0% |
| Mbx Biosciences, Inc. | 6.65M | US$367M | 8.0% |
| Arcutis Biotherapeutics, Inc. | 9.87M | US$259M | 5.6% |
| Trevi Therapeutics, Inc. | 9.94M | US$185M | 4.0% |
| Krystal Biotech, Inc. | 481K | US$179M | 3.9% |
| Maze Therapeutics, Inc. | 5.03M | US$150M | 3.3% |
| Phathom Pharmaceuticals, Inc. | 12.5M | US$135M | 2.9% |
| Palvella Therapeutics, Inc. | 882K | US$135M | 2.9% |
| Bridgebio Pharma, Inc. | 1.55M | US$115M | 2.5% |
| Disc Medicine, Inc. | 1.35M | US$99.1M | 2.2% |
| Cytokinetics, Incorporated | 1.16M | US$98.8M | 2.2% |
| Dyne Therapeutics, Inc. | 3.15M | US$70M | 1.5% |
| Ascendis Pharma A/s | 225K | US$60.1M | 1.3% |
| Savara, Inc. | 9.72M | US$59.9M | 1.3% |
| Parabilis Medicines, Inc. | 1.92M | US$52.6M | 1.1% |
| Aura Biosciences, Inc. | 7.1M | US$50.4M | 1.1% |
| Achieve Life Sciences, Inc. | 7.61M | US$49.7M | 1.1% |
| Vor Biopharma Inc. | 2.54M | US$46.8M | 1.0% |
| Allogene Therapeutics, Inc. | 22.4M | US$46.7M | 1.0% |
| Tarsus Pharmaceuticals, Inc. | 729K | US$45.9M | 1.00% |
| Biocryst Pharmaceuticals, Inc. | 4.01M | US$40.1M | 0.87% |
| Acadia Pharmaceuticals Inc. | 1.44M | US$36.4M | 0.79% |
| Zai Lab Ltd. | 1.9M | US$36.1M | 0.79% |
| Mannkind Corporation | 6.6M | US$28.1M | 0.61% |
| Design Therapeutics, Inc. | 1.81M | US$26.2M | 0.57% |
| Aclaris Therapeutics, Inc. | 4.93M | US$26.1M | 0.57% |
| Shattuck Labs, Inc. | 3.75M | US$26M | 0.57% |
| Kailera Therapeutics, Inc. | 1.1M | US$24.2M | 0.53% |
| Monte Rosa Therapeutics, Inc. | 1M | US$24.2M | 0.53% |
| Lexeo Therapeutics, Inc. | 4.82M | US$22.5M | 0.49% |
| Relay Therapeutics, Inc. | 1.02M | US$19M | 0.41% |
| Evolus, Inc. Common Stock | 2.63M | US$18.3M | 0.40% |
| Valneva Se | 2.29M | US$12M | 0.26% |
| Xilio Therapeutics, Inc. | 423K | US$4.05M | 0.09% |
| Ibio, Inc. | 1.95M | US$3.42M | 0.07% |
| Agios Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Kalvista Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |
| Revolution Medicines, Inc. | 0 | US$0 | 0.00% |
Source
View original at SEC
Related